Similar articles for PMID: 27622340

Year	Number of Results
2004	1
2006	3
2007	1
2008	1
2009	2
2010	2
2011	2
2012	2
2013	2
2014	5
2015	7
2016	8
2017	12
2018	11
2024	0

1

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. Karoulia Z, et al. Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. Cancer Cell. 2016. PMID: 27622340 Free article. No abstract available.

2

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. King AJ, et al. Cancer Res. 2006 Dec 1;66(23):11100-5. doi: 10.1158/0008-5472.CAN-06-2554. Cancer Res. 2006. PMID: 17145850

3

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB. Chen SH, et al. Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5. Cancer Discov. 2016. PMID: 26732095

4

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.

Heard JJ, Phung I, Potes MI, Tamanoi F. Heard JJ, et al. BMC Cancer. 2018 Jan 10;18(1):69. doi: 10.1186/s12885-017-3938-5. BMC Cancer. 2018. PMID: 29320991 Free PMC article.

5

Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF^V600E mutant cancer.

Hong SP, Ahn SK. Hong SP, et al. Life Sci. 2017 Aug 15;183:37-44. doi: 10.1016/j.lfs.2017.06.021. Epub 2017 Jun 21. Life Sci. 2017. PMID: 28645859

6

Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.

Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M. Lee MH, et al. J Clin Endocrinol Metab. 2011 Jan;96(1):E19-30. doi: 10.1210/jc.2010-1071. Epub 2010 Oct 6. J Clin Endocrinol Metab. 2011. PMID: 20926530

7

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. Okimoto RA, et al. Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. doi: 10.1073/pnas.1610456113. Epub 2016 Nov 9. Proc Natl Acad Sci U S A. 2016. PMID: 27834212 Free PMC article.

8

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S. Nakamura A, et al. Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11. Cancer Res. 2013. PMID: 24121489

9

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD. Shao W, et al. Cancer Res. 2018 Mar 15;78(6):1537-1548. doi: 10.1158/0008-5472.CAN-17-2033. Epub 2018 Jan 17. Cancer Res. 2018. PMID: 29343524

10

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.

Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF. Vakana E, et al. Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002. Oncotarget. 2017. PMID: 27999210 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

50 results

Results by year